» Articles » PMID: 10893497

Haplotype Transmission Disequilibrium and Evidence for Linkage of the CHRNA7 Gene Region to Schizophrenia in Southern African Bantu Families

Overview
Journal Am J Med Genet
Specialty Genetics
Date 2000 Jul 14
PMID 10893497
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Recent reports have strongly linked markers near the alpha-7 nicotinic cholinergic receptor subunit gene on human chromosome 15q13-q14 to a sensory gating deficit common in schizophrenics, and have shown positive though non-significant results linking this region to the primary phenotype of schizophrenia in a sample of North American families. We therefore tested for linkage between markers in this region of chromosome 15q and schizophrenia in a sample of 15 multiply affected and 5 single case families with schizophrenia drawn from the Bantu-speaking black population of South Africa. An initial replication using markers from the original study gave an affected-only LOD score maximum of 1.08 under a recessive model at Theta=0.00 for D15S1360, a dinucleotide polymorphism found on the same YAC as the alpha-7 receptor gene. Nonparametric affected-only multipoint analysis gave a Z-score of 1. 29, P=0.098, for D15S1360, and Z=1.45, p=0.075 for D15S118. We then increased the resolution of the map with an extended set of 20 markers. Again, two peaks were observed, with NPL scores of 1.81, p=0.037, at D15S1043 and 1.79 at D15S1360 and 1.80 at D15S1010, both p=0.037. Transmission disequilibrium testing of data from D15S1360 gave an allele-wise and genotype-wise chi(2) of 6.59, 2 df, p=0.037. Haplotype transmission disequilibrium testing using a restricted allele and haplotype set from D15S1043 and D15S1360 gave a global chi(2) of 10.647, 4 df, P=0.007, and a maximum chi(2) of 6.567, 1 df, P=0.004 for excess transmission of the 1.2 haplotype into affected offspring. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:196-201, 2000.

Citing Articles

Family, twin and adoption studies of severe mental disorders in sub-Saharan Africa: a scoping review.

Onu J, Olatayo T, Okorie A, Ohaeri J Soc Psychiatry Psychiatr Epidemiol. 2022; 58(5):685-692.

PMID: 36542114 DOI: 10.1007/s00127-022-02407-7.


Approved and emerging smoking cessation treatments for people with schizophrenia spectrum disorders: A narrative review.

Caponnetto P, Polosa R Health Psychol Res. 2020; 8(2):9237.

PMID: 33123649 PMC: 7588850. DOI: 10.4081/hpr.2020.9237.


Tobacco smoking, related harm and motivation to quit smoking in people with schizophrenia spectrum disorders.

Caponnetto P, Polosa R, Robson D, Bauld L Health Psychol Res. 2020; 8(1):9042.

PMID: 32510003 PMC: 7267811. DOI: 10.4081/hpr.2020.9042.


Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.

Tregellas J, Wylie K Nicotine Tob Res. 2018; 21(3):349-356.

PMID: 30137618 PMC: 6379034. DOI: 10.1093/ntr/nty034.


Molecular substrates of schizophrenia: homeostatic signaling to connectivity.

Landek-Salgado M, Faust T, Sawa A Mol Psychiatry. 2015; 21(1):10-28.

PMID: 26390828 PMC: 4684728. DOI: 10.1038/mp.2015.141.